Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of V565 in Healthy Volunteers and Crohn's Disease
NCT03010787Phase 1Completed
- Sponsor
- VHsquared Ltd.
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V565 in Crohn's disease (5 arms), sponsored by VHsquared Ltd. Primary endpoints: Treatment-emergent adverse events, physical examinations, safety lab tests, ECGs, vital signs at 14 days and Concentration of V565 in ileal fluid at 24 hours. Started Sep 2015; status: completed.
02
Drugs
V565
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03010787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010787.